Response Adapted incorporation of Tislelizumab into the Front-line treatment of older patients with Hodgkin lYmphoma (RATIFY)

Research summary

RATiFY is a non-randomised,multicentre,phase II trial. Eighty patients will be recruited and,following initial treatment with 3 cycles of tislelizumab and PET-CT with ceCT scan,will be assigned to 1 of 5 treatment groups (Groups A to E) based on disease stage,risk,and response. Patients with early stage lymphoma showing good response (Group A) will receive radiotherapy and further tislelizumab for up to 2 years,but no chemotherapy. All other patients (Groups B-E) will receive further tislelizumab with AVD chemotherapy for between 2 and 6 cycles,and may also receive radiotherapy depending on disease stage.

Principal Investigator

Dr Graham Collins

Contact us

Email: Latephasehaematology@ouh.nhs.uk

IRAS number

1005530